Kraig Labs achieves key milestone in spider silk production.

Kraig Biocraft Laboratories (KBLB) announced a significant advancement in their quest to commercialize spider silk technology. They achieved homozygosity for the spider silk gene in both parents of their BAM 1 hybrid, a crucial step for efficient production. Homozygosity ensures offspring consistently inherit the desired gene, leading to higher spider silk protein expression. This achievement, ahead of spring trials, optimizes the BAM 1 hybrid for commercial production.

CEO Kim Thompson announced their team successfully met the aggressive deadline for achieving homozygosity, positioning the company for an exciting year ahead and the launch of their revolutionary spider silk technology. This breakthrough paves the way for Kraig Labs to potentially become a major player in the high-performance fiber industry, with spider silk applications spanning various sectors.